These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 19475777)
1. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Micieli G; Marcheselli S; Tosi PA Vasc Health Risk Manag; 2009; 5(1):397-409. PubMed ID: 19475777 [TBL] [Abstract][Full Text] [Related]
2. Treating as early as possible with thrombolysis is crucial, but can we do better in the sub-4.5-hour time window? Parsons MW Cerebrovasc Dis; 2011; 31(3):229. PubMed ID: 21178346 [No Abstract] [Full Text] [Related]
3. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Shobha N; Buchan AM; Hill MD; Cerebrovasc Dis; 2011; 31(3):223-8. PubMed ID: 21178345 [TBL] [Abstract][Full Text] [Related]
5. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan. Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704 [TBL] [Abstract][Full Text] [Related]
7. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke. Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152 [TBL] [Abstract][Full Text] [Related]
8. Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia. Al Khathaami AM; Al Bdah B; Tarawneh M; Alskaini M; Alotaibi F; Alshalan A; Almuhraj M; Aldaham D; Alotaibi N J Stroke Cerebrovasc Dis; 2020 May; 29(5):104761. PubMed ID: 32173225 [TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous thrombolysis in ischemic stroke caused by left atrial myxoma. Acampa M; Tassi R; Guideri F; Marotta G; Monti L; Capannini G; Cerase A; Martini G Curr Drug Saf; 2011 Nov; 6(5):343-5. PubMed ID: 22424543 [TBL] [Abstract][Full Text] [Related]
10. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Schmülling S; Rudolf J; Strotmann-Tack T; Grond M; Schneweis S; Sobesky J; Thiel A; Heiss WD Cerebrovasc Dis; 2003; 16(3):183-90. PubMed ID: 12865603 [TBL] [Abstract][Full Text] [Related]
11. Safety of standard-dose (.9-mg/kg) alteplase intravenous thrombolysis for acute ischemic stroke in Afro-Caribbeans, French West Indies. Chausson N; Olindo S; Joux J; Saint-Vil M; Aveillan M; Smadja D J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1776-80. PubMed ID: 24957315 [TBL] [Abstract][Full Text] [Related]
12. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341 [TBL] [Abstract][Full Text] [Related]
13. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke. Liu J; Shi Q; Sun Y; He J; Yang B; Zhang C; Guo R J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):1126-1132. PubMed ID: 30655038 [TBL] [Abstract][Full Text] [Related]
15. Role of tissue plasminogen activator in acute ischemic stroke. Hatcher MA; Starr JA Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027 [TBL] [Abstract][Full Text] [Related]
16. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis. Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038 [TBL] [Abstract][Full Text] [Related]
17. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D; N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396 [TBL] [Abstract][Full Text] [Related]
18. Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data? Barer D; Berge E Drugs Aging; 2017 Feb; 34(2):79-88. PubMed ID: 28120326 [TBL] [Abstract][Full Text] [Related]
19. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study. Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101 [TBL] [Abstract][Full Text] [Related]
20. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke. Zhang B; Sun XJ; Ju CH Eur Neurol; 2011; 65(3):170-4. PubMed ID: 21372577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]